Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2413555 in Chronic Heart Failure with ICD/CRT
NCT05532046Phase 1Terminated
- Sponsor
- Bayer
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of BAY2413555 in chronic heart failure (CHF) (3 arms), sponsored by Bayer. Primary endpoint: Treatment-emergent adverse events at 56 days. Started Sep 2022; status: terminated.
02
Drugs
BAY2413555
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT05532046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532046.